LEXINGTON, Mass. & CLEVELAND--(BUSINESS WIRE)-- GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that Stuart A. Randle, chief executive officer, will participate in a panel discussion as part of the 2010 Medical Innovation Summit being held at the Cleveland Clinic November 1-3, 2010 in Cleveland, Ohio. The focus of this year’s summit, obesity, diabetes and the metabolic crisis, will bring together international leaders and researchers in healthcare to share their perspectives and discuss innovations in the way these diseases may be prevented, managed and treated.
“Forums like the Medical Innovation Summit provide an opportunity to engage, educate and learn about existing best practices and new treatment approaches that will help improve and manage these twin epidemics, and shape the future of patient care,” said Mr. Randle. “I am pleased to be part of this forum, and appreciate the opportunity to contribute our thinking and insights gleaned from our efforts to develop the EndoBarrier, a non-surgical therapeutic for the treatment of type 2 diabetes and obesity.”
Mr. Randle will participate in a panel, “The Revolution in Diabetes Treatment, Surgical Intervention & Novel Therapies Explored,” on November 3, 2010 at 9:10 a.m. (EDT). Panelists will discuss forthcoming diabetes disease management and therapeutic treatment options, including GI Dynamics’ EndoBarrier Gastrointestinal Liner.
About the EndoBarrier™ Gastrointestinal Liner
The patented EndoBarrier Gastrointestinal Liner is a non-surgical medical device based on the EndoBarrier Technology platform for treating type 2 diabetes and obesity. The EndoBarrier Gastrointestinal Liner is approved for use in Europe and is an advanced investigational device in the United States. The EndoBarrier Gastrointestinal Liner is placed in the GI tract endoscopically (via the mouth) to create a barrier between food and the wall of the intestine. Physicians believe that preventing food from coming into contact with the intestinal wall may alter the activation of hormonal signals that originate in the intestine, thus mimicking the effects of a Roux-en-Y gastric bypass procedure without surgery. A growing body of preclinical and clinical evidence supports the potential for EndoBarrier Gastrointestinal Liner to change the treatment landscape for people living with one or more of the of following conditions: type 2 diabetes, obesity and at risk for type 2 diabetes, and severe weight problems. For more information, please visit www.endobarrier.com.
About GI Dynamics
GI Dynamics is focused on developing effective, non-surgical therapeutics for treating type 2 diabetes and obesity. The company’s patented EndoBarrier™ Technology has the potential to deliver medical interventions for people combating weight problems and diabetes or diabetes risk factors. Data from clinical trials demonstrate that the EndoBarrier™ Gastrointestinal Liner may provide rapid improvement in glycemic control and significant weight loss by modifying metabolic pathways.
Based in Lexington, Massachusetts and founded in 2003, GI Dynamics is backed by top-tier investors including Advanced Technology Ventures, Catalyst Health Ventures, Cutlass Capital, Domain Associates, Johnson & Johnson Development Corporation, Medtronic, Inc. and Polaris Venture Partners. For more information, visit GI Dynamics online at www.gidynamics.com.
CONTACT:
Pure Communications Inc.
Caton Lovett, 910-232-7166
KEYWORDS: United States North America Massachusetts Ohio
INDUSTRY KEYWORDS: Health Clinical Trials Hospitals Medical Devices General Health
MEDIA: